Evaluation of the health care budget impact of secukinumab treatment in patients with ankylosing spondylitis

Evaluation of the health care budget impact of secukinumab treatment in patients with ankylosing spondylitis

Objective: clinical and economic analysis of including of secukinumab (SEC) in the essential drug list (EDL) and Federal Reimbursement (ONLS) to ensure the availability of the drug to patients with ankylosing spondylitis (AS) at the expense of health. Material and methods. A budget impact analysis w...

Full description

Bibliographic Details
Main Authors:	S. K. Zyryanov, I. N. Dyakov, S. V. Nedogoda, M. Yu. Frolov, A. S. Salasyuk
Format:	Article
Language:	Russian
Published:	IMA-PRESS LLC 2017-04-01
Series:	Современная ревматология
Subjects:	анализ затрат анализ влияния на бюджет фармакоэкономика клинико-экономический анализ секукинумаб адалимумаб инфликсимаб генно-инженерные биологические препараты анкилозирующий спондилит болезнь бехтерева
Online Access:	https://mrj.ima-press.net/mrj/article/view/761

Similar Items

Cost-effectiveness study of treatment with biologic disease-modifying antirheumatic drugs in adult patients with active ankylosing spondylitis
by: R. O. Dreval
Published: (2021-02-01)

Evaluating the effect of a Russian rituximab biosimilar used to treat patients with rheumatoid arthritis on healthcare budgets
by: R. O. Dreval
Published: (2018-06-01)

CLINICAL AND ECONOMIC ANALYSIS OF GENETICALLY ENGINEERED BIOLOGICS CONSUMPTION BY PATIENTS WITH COVID-19
by: V. I. Petrov, et al.
Published: (2022-05-01)

Clinical and economic efficiency of treatment with dapagliflozin of patients with type 2 diabetes mellitus in Russian health care conditions
by: S. K. Zyryanov, et al.
Published: (2020-04-01)

Pharmacoeconomic evaluation of ipragliflozin in combination with metformin in comparison with other regimens of therapy for type 2 diabetes mellitus
by: A. S. Kolbin, et al.
Published: (2021-02-01)

Pharmacoeconomic analysis of using biological agents in the treatment of rheumatoid arthritis
by: I. I. Dyakov, et al.
Published: (2014-09-01)

Recent advances and prospects of axial spondyloarthritis / ankylosing spondylitis treatment
by: Sh. F. Erdes
Published: (2021-04-01)

Clinical and economic analysis of macrocyclic gadolinium-based compounds for use in magnetic resonance imaging diagnostics
by: A. E. Cheberda, et al.
Published: (2020-01-01)

Фармакоэкономический анализ применения бортезомиба для подкожного введения у пациентов с рецидивирующей множественной миеломой
Published: (2018-06-01)

Pharmacoeconomic analysis of subdermal tocilizumab in patients with rheumatoid arthritis
by: S. K. Zyryanov, et al.
Published: (2018-05-01)

Тяжелое течение анкилозирующего спондилита с резистентностью к медикаментозной терапии (клинические наблюдения)
Published: (2018-06-01)

Pharmacoeconomic analysis of perampanel for resistance partial epilepsy
by: D. Yu. Belousov, et al.
Published: (2018-06-01)

Giant cell arteritis. Part III. New trends in its treatment (role of genetically engineered drugs)
by: Azamat Makhmudovich Satybaldyev
Published: (2013-03-01)

The effectiveness of switching from an originator biological agent to its biosimilar, or vice versa, for ankylosing spondylitis in real clinical practice
by: K. V. Sakharova, et al.
Published: (2020-11-01)

THE POSSIBILITIES AND RESULTS OF INDIRECT COMPARISON OF BIOLOGICAL AGENTS IN ANKYLOSING SPONDYLITIS
by: Sh. F. Erdes
Published: (2016-12-01)

harmacoeconomic feasibility of using the drug upadacitinib in patients with rheumatoid arthritis in the healthcare system of the Russian Federation
by: A. M. Lila, et al.
Published: (2020-09-01)

Pharmacoeconomic rationale for switching patients with rheumatic diseases from original biologic disease-modifying antirheumatic drugs to biosimilars in context of the Russian healthcare system
by: A. Yu Kulikov, et al.
Published: (2022-06-01)

Management of Moderate and Severe Forms of Psoriasis in Children: New Opportunities of Genetically Engineered Biologic Drugs
by: Leyla S. Namazova-Baranova, et al.
Published: (2021-11-01)

Pharmacoeconomic analysis of naft idrofuryl in patients with chronic obliterating diseases of lower limb arteries
by: A. E. Cheberda, et al.
Published: (2018-05-01)

Assessment of the economic feasibility of gadoversetamida (OptiMARK) MRI with intravenous contrast
by: A. S. Kolbin, et al.
Published: (2018-06-01)

Экономическая эффективность применения гефитиниба в качестве терапии 1-й линии у пациентов с распространённым немелкоклеточным раком лёгкого при наличии мутации в гене EGFR
Published: (2018-06-01)

Pharmacoeconomic analysis of Actemra<sup>®</sup> in first-line treatment of rheumatoid arthritis in the modes of combination and monotherapy
by: S. K. Zyryanov, et al.
Published: (2018-05-01)

Description of the Clinical Case of Adalimumab and Secukinumab Therapy of a Patient with Psoriatic Arthritis
by: V. V. Didenko, et al.
Published: (2021-05-01)

Switching to a Second TNF-α Inhibitor in a Patient with Severe Juvenile Polyarthritis: A Clinical Case
by: Ekaterina V. Denisova, et al.
Published: (2018-10-01)

Pharmacoeconomic analysis of flexible-dose administration regimen of Xeomine® in patients with focal dystonia
by: A. E. Cheberda, et al.
Published: (2018-06-01)

Pharmacoeconomic feasibility of using Mirabegron in patients with overactive bladder
by: I. N. Dyakov, et al.
Published: (2021-04-01)

THE EXPERIENCE OF SWITCHING TO THE SECOND TNF INHIBITOR IN A PATIENT WITH SEVERE JUVENILE POLYARTHRITIS AND RESISTANCE TO THE FIRST TNF-BLOCKER
by: Ekaterina I. Alexeeva, et al.
Published: (2017-09-01)

Проспективное сравнительное клинико-экономическое исследование терапевтической эффективности ТОБРЕКС® 2Х и ТОБРОПТ при лечении бактериальных конъюнктивитов
Published: (2018-06-01)

Pharmacoeconomic evaluation of the ceftolosan + tasobactam in the treatment of complicated nosocomial intraabdominal infections
by: I. N. Dyakov, et al.
Published: (2019-10-01)

Клинико-экономический анализ оригинальной и генерической форм клопидогрела при ишемической болезни сердца после эндоваскулярных вмешательств
Published: (2018-06-01)

New etanercept biosimilar — expanding treatment options for immune-mediated inflammatory rheumatic diseases
by: A. E. Karateev, et al.
Published: (2022-12-01)

Inhibitors of interleukin 17A in the treatment of psoriatic arthritis: what's new?
by: Т. V. Korotaeva
Published: (2021-04-01)

Клинико-экономический анализ лечения хронического апикального периодонтита
Published: (2020-04-01)

Budget impact of eribulin in metastatic breast cancer in Russian Federation
by: S. K. Zyryanov, et al.
Published: (2018-05-01)

Comorbid infections in spondyloarthritis: a modern view of the problem
by: N. V. Muravyeva, et al.
Published: (2020-11-01)

OPTIMIZATION OF PHARMACEUTICAL CARE FOR JUVENILE RHEUMATOID ARTHRITIS AT THE REGIONAL LEVEL
by: A. A. Skripko, et al.
Published: (2018-01-01)

Comparative pharmacoeconomic analysis of the use of Bonviva® (ibandronat) to prevent fractures in postmenopausal osteoporosis
by: E A Pyadushkina, et al.
Published: (2012-12-01)

Experience with early use of certolizumab pegol in able-bodied patients with axial spondyloarthritis in the framework of a model for clinical statistical groups
by: Yu. Yu. Grabovetskaya
Published: (2020-09-01)

Clinical and economic analysis of biologic drugs in treatment of psoriasis
by: A. A. Kubanov, et al.
Published: (2018-05-01)

Pharmacoeconomic study of the effectiveness of cytogenetic studies in patients with MM before prescribing first-line therapy
by: Yu. A. Zabolotneva, et al.
Published: (2024-02-01)